Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).

Clinical genitourinary cancer - 1 Mar 2026

Park Joseph J, Howard Lauren E, Fragkogianni Stamatina, George Daniel J, Armstrong Andrew J

Abstract excerpt

INTRODUCTION: Inactivating missense mutations in the SPOP gene increase the transcriptional activity of the androgen receptor and sensitivity to hormonal therapies in patients with hormone sensitive prostate cancer (HSPC). However, the relationship of SPOP alterations with differential outcomes by race, particularly in patients with castration-resistant prostate cancer (CRPC), remains unclear. PATIENTS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Receptor Antagonists
Share to Nuclear Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Progression-Free Survival

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Share to Repressor Proteins

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41667321
DOI: 10.1016/j.clgc.2026.102502
PMCID: PMC12976783

Genes

SPOP
APC
AR
CDKN1B

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).PMID 41667321Read ↗

SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

SPOP Mutations in Veterans With Prostate Cancer and Outcomes With Doublet and Triplet Therapy in De Novo Metastatic Hormone Sensitive Prostate Cancer.Semantic proximity Read ↗

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Clinical and genomic features of SPOP‐mutant prostate cancerSemantic proximity Read ↗

Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation SequencingSemantic proximity Read ↗

Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.Semantic proximity Read ↗

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.Semantic proximity Read ↗

Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancerSemantic proximity Read ↗

Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer.Semantic proximity Read ↗

Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate CancerSemantic proximity Read ↗

Prognostic value of the SPOP mutant genomic subclass in prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.